PRODUCT MONOGRAPH

AtlantiScan

(^{18}F-Fluorodeoxyglucose (^{18}F-FDG))

Parenteral Solution, up to 7.4 GBq/mL
Diagnostic Radiopharmaceutical

Nova Scotia Health Authority, Diagnostic Imaging
Victoria General Site
1276 South Park Street
Halifax, NS B3H 2Y9

Date of Approval: June 29, 2015
Submission Control No: 184655

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intravenous	Parenteral Solution / Contain up to 7.4 GBq/mL (200 mCi/ml) in a 25mL vial	None

Fludeoxyglucose F 18 Injection is a positron-emitting radiopharmaceutical used as an accessory to Positron Emission Tomography (PET) for the assessment of abnormal glucose metabolism.

The active ingredient 2-deoxy-2-[^{18}F]fluoro-D-glucose, abbreviated ^{18}F-FDG, differs from glucose only in having a radioactive fluorine (^{18}F) in the 2 position. The 18F atom decays into 18O, converting the molecule into D-[2-^{18}O] glucose, an isotopologue of glucose.



D-glucose



2-deoxy-2-[^{18}F]fluoro-D-glucose



D-[2-^{18}O]glucose

DESCRIPTION

Physical Characteristics

Fluorine F 18 decays by positron (β+) emission and has a half-life of 109.7 minutes. The fractions remaining at selected intervals after calibration are shown in Table 1.

Table 1. Physical Decay Chart for Fluorine F18

Time from Calibration	Fraction remaining %
15 min	91
30min	83
45 min	75
60 min	68
75 min	62
90 min	57
120 min	47
150 min	39
180 min	32
210 min	27
240 min	22

The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 2).

Talbe 2: Principal Emission Data for Fluorine F 18

Radiation/Emission	% per Disintegration	Mean Energy
Positron (β^+,e^+)	96.73	249.8 keV
Gamma (γ)**	193.46	511.0 keV

***D. C. Kocher*, *Radioactive Decay Tables* - A Handbook of *Decay* Data for Application to Radiation Dosimetry and Radiological Assessments, DOE/TIC-11026 (1981)

External Radiation

The specific gamma-ray constant for fluorine F 18 is 6.0 R/hr/mCi at 1cm. The narrow-beam attenuation half-value layer is 4.1 mm for lead (and 3.4 cm for concrete). Broad-beam transmission factors at 511 keV for various thicknesses of lead are given in Table 3.

Table 3. Broad-beam transmission factors at 511 keV in lead

mmPb	Transmission
1	0.89
2	0.79
3	0.69
4	0.60
5	0.52
6	0.45
7	0.39
8	0.34
9	0.29
10	0.25
12	0.18
14	0.13
16	0.10
18	0.07
20	0.05
30	0.01

INDICATIONS AND CLINICAL USE

AtlantiScan (Fludeoxyglucose F 18 Injection) is indicated as an accessory to positron emission tomography (PET) imaging, in patients with known or suspected abnormalities found by other testing modalities, for the assessment of abnormal glucose metabolism to assist in:

- The characterization of solitary pulmonary nodules;
- The staging of lung cancer;
- The detection of recurrence in patients with previously diagnosed lung cancer; and
- The monitoring of the therapeutic response in patients with lung cancer.

The uptake of ^{18}F-FDG is not cancer-specific. False-positives may occur in non-malignant areas of high metabolic activity, such as infection, inflammation, granulomatous reactions, and tissue repair. False negative results may occur in malignant tumors with low glycolytic activity, in tumors with large mucinous components, in some bronchioloalveolar carcinomas (*e.g.*, localized), in small-sized tumors (< 2 times system resolution), and in hyperglycemic states (See *Dosage and Administration*, *Image Interpretation*)

CONTRAINDICATIONS

^{18}F-FDG should not be administered to patients who are hypersensitive to Fludeoxyglucose F18.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Radiopharmaceuticals should be used only by those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.

^{18}F-FDG should not be administered to pregnant women unless it is considered that the benefits to be gained outweigh the potential hazards to the foetus.

There is little secretion of ^{18}F-FDG in breast milk but there is a high uptake of ^{18}F-FDG in a lactating, suckled breast. Where an assessment of the risk benefit ratio suggests the use of ^{18}F-FDG in nursing woman, breastfeeding should be discontinued, and close contact between mother and infant avoided, for a period of 12 hours following an ^{18}F-FDG PET scan.

General

Precautions related to the handling of radioactive material must be observed in the handling and utilization of this product including those concerning radioactive patients. Only those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans shall use radiopharmaceuticals.

The product should be administered under the supervision of a health professional that is experienced in the use of radiopharmaceuticals. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available.

The radiopharmaceutical product may be received, used and administered only by authorized persons in designated clinical settings. Its receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of local competent official organizations.

As in the use of any other radioactive material, care should be taken to minimize radiation exposure to patients consistent with proper patient management, and to minimize radiation exposure to occupational workers.

Carcinogenesis and Mutagenesis
Studies with Fludeoxyglucose F18 Injection have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility (see also *Pregnant women*, below).

Contamination
The following measures should be taken for up to 12 hours after receiving the radiopharmaceutical product: Toilet should be used instead of urinal. Toilet should be flushed several times after use.

Special precautions such as bladder catheterization should be taken following administration to incontinent patients to minimize the risk of radioactive contamination of clothing, bed linen and the patient's environment.

Endocrine and Metabolism
Use in patients with diabetes or hyperglycemia has not been well studied. It is recommended that patients be normoglycemic when undergoing PET imaging with Fludeoxyglucose F 18 Injection.

Transport of Fludeoxyglucose F18 into cells may be affected by fasting or by blood glucose changes associated with diabetes mellitus. Diabetic patients may need stabilization of blood glucose levels on the day before and on the day of administration of Fludeoxyglucose F-18 Injection.

Special Populations
Pregnant Women: Ideally examinations using radiopharmaceuticals, especially those elective in nature of women of childbearing capability should be performed during the first ten days following the onset of menses.

Since adequate reproduction studies have not been performed in animals to determine whether this drug affects fertility in males or females, has teratogenic potential, or has other adverse reactions on the fetus, this radiopharmaceutical preparation should not be administered to pregnant women unless it is considered that the potential benefits outweigh the potential hazards to the fetus.

The fetus would receive a radiation dose of 10 mGy (Fetal dose is estimated at 2.2 x 10^{-2} mGy/MBq; see Radiation Dosimetry below) from a 455 MBq maternal dose (7.5 MBq/kg to a 60 kg women). This level of radiation can increase the risk of leukemia and other cancers by 40%[1]. The use of a lower dose of [^{18}F]-FDG, maternal hydration, and frequent voiding can reduce the radiation dose to the fetus.

Nursing Women: There is little secretion of Fludeoxyglucose F18 Injection in breast milk but there is a high uptake of Fludeoxyglucose F 18 injection in a lactating, suckled breast[2]. The infant from close contact receives a higher radiation dose from the breast than from ingestion of radioactive milk. Breastfeeding should be discontinued, and close

contact between mother and infant avoided, for a period of 12 hours following an ^{18}F-FDG PET scan.

Pediatrics: The safety and effectiveness of Fludeoxyglucose F 18 Injection in the approved indication has not been established in pediatric patients. Fludeoxyglucose F 18 Injection has been safely and effectively used in pediatric patients for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

Geriatrics: Geriatric patients were included in the studies demonstrating the efficacy and safety of 18F-FDG in the approved indication. There are no known limitations on the clinical use of Fludeoxyglucose F18 Injection in geriatric patients.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

A systematic review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems indicated that adverse reactions have not been reported for Fludeoxyglucose F 18 Injection.

In a large published study in 22 PET centers, no adverse reactions to positron-emitting radiopharmaceuticals, primarily ^{18}F-FDG, were reported retrospectively for 33,295 doses and prospectively for 47,876 doses[3].

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In a 7,710-patient prospective clinical trial, no adverse reactions attributable to ^{18}F-FDG were reported.

Less Common Clinical Trial Adverse Drug Reactions (<1%)

In a 7,710-patient prospective clinical trial, there were 6 reports of skin rash (6/7710; 0.08%), without pruritus or other accompanying signs or symptoms; all reported 24 hours after the procedure. A relationship to ^{18}F-FDG can neither be inferred nor denied.

Abnormal Hematologic and Clinical Chemistry Findings

Not applicable.

Post-Market Adverse Drug Reactions

Not applicable.

DRUG INTERACTIONS

Interactions with drugs, food, herbs, and laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Dosing considerations

Patients should fast for at least 4 hours prior to dosing. Blood glucose should be assessed prior to dosing. Hyperglycemic patients should have their blood glucose level normalized prior to dosing.

Patients should be well hydrated and should be encouraged to drink sufficient amounts of water to permit frequent bladder emptying, especially immediately prior to and after the PET examination.

Patients should avoid all strenuous physical activity prior to the examination and remain at rest between the injection and examination.

Dosage

The optimal dose of ^{18}F-FDG has not been systematically investigated and may vary according to the imaging equipment used, the delay from administration to imaging, and to patient characteristics. The usual recommended adult dose is 7.5 MBq/kg (370 to 740 MBq).

Administration

The dose of ^{18}F-FDG should be measured by a suitable radioactivity calibration system prior to intravenous administration. The intravenous injection should be on the contralateral side to the site of concern.

Image Acquisition and Interpretation

Image acquisition parameters and procedures will vary depending upon the clinical question and the type of equipment available.

The optimal time from dosing to imaging has not been systematically investigated. Images are generally acquired 30 to 60 minutes after the administration of ^{18}F-FDG but later imaging times are also frequently used.

Only experienced nuclear medicine physicians familiar with the normal and condition-specific physiological and anatomical variants of ^{18}F-FDG biodistribution should interpret ^{18}F-FDG-PET images.

Physicians should be aware of patient preparation anomalies (*e.g.,* marginally acceptable blood glucose level and heightened anxiety state), and relevant patient history (*e.g.* recent and current health problems, recent surgeries and radiation treatments, menstrual and lactation status).

The uptake of ^{18}F-FDG is not cancer-specific. False positive findings may occur in non-malignant areas of high metabolic activity, such as infection (mycobacterial, fungal, bacterial infection), inflammatory and especially granulomatous reactions (*e.g.*, bronchiectasis, sarcoidosis, pleurodesis, radiotherapy sites, and active atheromas) and tissue repair (trauma, post- surgery).

False-negatives have been reported in tumors with low glycolytic activity (*e.g.*, adenomas; bronchioloalveolar, mucinous, and lobular carcinomas; carcinoid tumors, and fibroadenoma), and in small-sized tumors (< 1 cm). ^{18}F-FDG competes with blood glucose for uptake; increased levels of blood glucose can interfere with the uptake of ^{18}F-FDG by malignant cells and result in false negative findings.

Instructions for Preparation and Use

The components of the vial are sterile and non-pyrogenic. It is essential that the user follows the directions carefully and adheres to strict aseptic technique. Use aseptic technique and wear waterproof gloves throughout the entire preparation procedure. Make all transfers of radioactive solutions with an adequately shielded syringe and maintain adequate shielding around the vial during the useful life of the radioactive product.

Directions for Quality Control

The required quality control testing has been performed on the product prior to release.

RADIATION DOSIMETRY

Based on ICRP 80, the effective dose resulting from the administration of 555 MBq of ^{18}F-FDG is 10.5 mSv. The whole body dose, based on MIRD dose estimates, is 6.7 mGy. For the critical organs bladder, heart, and brain, the (MIRD) estimated absorbed radiation doses from 555 MBq of ^{18}F-FDG are, respectively, 41 mGy, 38 mGy, and 26 mGy.

The estimated absorbed radiation doses are shown in Table 4.

Table 4. Estimated Absorbed Radiation Doses after IV 18FDG

Target organ	mGy/MBq	rad/mCi
Brain	0.046 ± 0.012	0.170 ± 0.044
Heart wall	0.068 ± 0.036	0.250 ± 0.130
Kidneys	0.021 ± 0.0059	0.078 ± 0.022
Liver	0.024 ± 0.0085	0.088 ± 0.031
Lungs	0.015 ± 0.0084	0.056 ± 0.031
Pancreas	0.014 ± 0.0016	0.052 ± 0.0060
Red marrow	0.011 ± 0.0017	0.040 ± 0.0062
Spleen	0.015 ± 0.0021	0.056 ± 0.0078
Urinary bladder wall	0.073 ± 0.042	0.270 ± 0.160
Ovaries	0.011 ± 0.0015	0.041 ± 0.0055
Testes	0.011 ± 0.0016	0.041 ± 0.0057
Whole body	0.012 ± 0.00077	0.043 ± 0.0023

MIRD Dose Estimate Report No. 19[4]

The fetal dose estimates are: 2.2 x 10-2 mGy/MBq in early pregnancy and at 3-months gestation, and 1.7 x 10-2 mGy/MBq at 6 and 9 months gestation.[5]

OVERDOSAGE

Cases of overdose are not known to have occurred with 18F-FDG. In case of overdose, the patient should be monitored and managed as clinically indicated.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

^{18}F-FDG is transported in a manner similar to glucose from blood to tissue where it is phosphorylated by hexokinase to ^{18}F-FDG-6-phosphate. As ^{18}F-FDG-6-phosphate is not a substrate for subsequent glycolytic pathways, and has very low membrane permeability, ^{18}F-FDG becomes trapped in tissue in proportion to the rate of glycolysis or glucose utilization of that tissue. Imaging of the subject using a positron emission tomography (PET) scanner takes advantage of the positron decay of ^{18}F to identify those tissues that have an abnormal accumulation of the radioisotope.

In cancer, cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase of the glucose transporters, (2) an increase rate of phosphorylation activity, (3) a reduction of phosphatase activity or, (4) a dynamic alteration in the balance among all of these processes. However, glucose metabolism of cancer as reflected by ^{18}F-FDG accumulations shows considerable variability. Depending upon the tumor type, stage and location, ^{18}F-FDG accumulations may be increased, normal or decreased. Also, inflammatory cells can have the same variability of uptake of ^{18}F-FDG.

Pharmacodynamics

At the concentrations used for diagnostic examinations, ^{18}F-FDG does not have any pharmacodynamic activity.

Pharmacokinetics

Distribution:

^{18}F-FDG is widely distributed in the body following intravenous administration and equilibrates quickly between plasma and erythrocytes[6]. The brain, heart, and liver show the highest accumulation. The brain contains 3.9% of injected activity 33 minutes after dosing[7] and 6.9% of cumulated activity[8]. Other cumulated activities are urinary bladder, 6.3%; liver, 4.4%; heart, 3.3%; kidney, 1.3%; lung, 0.9%; spleen 0.4%; and pancreas 0.3%. Based on these results, cumulated activities have been estimated for red marrow, 1.7%; testes, 0.4%; and ovaries, 0.01%. The majority of ^{18}F-FDG distribution at 90 minutes is in tissues other than the blood, brain, heart and liver. These other tissues (probably the skeletal muscle and gut) become increasingly important with time and account for approximately 75% of the cumulated activity[6].

Mean residence times have been calculated from human data for plasma, 0.17 ± 0.06; erythrocytes, 0.10 ± 0.03; heart, 0.13 ± 0.06; lungs, 0.08 ± 0.03; liver, 0.16 ± 0.06, whole

brain,0.24 ± 0.09; and bladder, 0.04 ± 0.017, with voids at 0.5, 1, 2, then every 2 hours. Whole body residence time is 2.41 ± 0.09[6].

Metabolism:
^{18}F-FDG is phosphorylated to ^{18}F-FDG-6-phosphate by hexokinase, with no further metabolism taking place.

Excretion:
^{18}F-FDG is mostly excreted unchanged in the urine; approximately 20% of the administered activity is recovered in the urine within the first 2 hours[7,8].

Special Populations and Conditions
No data available.

STORAGE AND STABILITY
Fludeoxyglucose F18 Injection should be stored upright in a lead shielded container at controlled room temperature. Fludeoxyglucose F18 Injection should be used within 12 hours from the time of the end of synthesis.

SPECIAL HANDLING INSTRUCTIONS
As in the use of any other radioactive material, care should be taken to minimize radiation exposure to patients consistent with proper patient management, and to minimize radiation exposure to occupational workers.

Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclide, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

DOSAGE FORMS, COMPOSITION AND PACKAGING
Fludeoxyglucose F18 Injection is supplied in a multi-dose, septum-caped, 25 mL, glass vial containing 370-7400 MBq/mL (10-200 mCi/mL) of no carrier added 2-deoxy-2-[18F]fluoro-D-glucose, at end of synthesis, in approximately 13 to 16 mL.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Chemical name: **USP and Ph Eur name** **Other names**	2-deoxy-2-(^{18}F)fluoro-D-glucose Fludeoxyglucose [^{18}F] injection [^{18}F]-fluorodeoxyglucose/ 2-Fluoro-2-deoxy-D-glucose
Pharmaceutical form	Clear, colourless solution for injection.
Route of Administration **CAS registry number:**	Intravenous 63503-12-8(^{18}F-FDG); 29702-43-0(19F-FDG)
PubChem **Chemical formula:**	68614 $C_8H_{11}{}^{18}FO_5$
Molecular mass:	181.26 g/mol
Chemical structure:	
Solubility **[^{18}F]t $_{1/2}$**	soluble in water 109.8 min

Product Characteristics

Fludeoxyglucose F18 Injection is provided as a ready to use sterile, clear, colorless solution. Each mL contains between 370 to 7400 MBq (10 – 200 mCi) of 2-deoxy-2-[18F]fluoro-D glucose at the end of synthesis (EOS). The pH of the solution is between 4.5 to 7.5. The solution is packaged in a multiple-dose glass vial and does not contain any preservative.

CLINICAL TRIALS

AtlantiScan (Fludeoxyglucose F18 Injection) was authorized as an Abbreviated New Drug Submission (ANDS).

The focus of the ANDS was a physicochemical-based comparison; no clinical trial data were generated and submitted for this product. The Canadian Reference Product (CRP) cited in this ANDS was ^{18}F-Fluorodeoxyglucose (^{18}F-FDG) (PharmaLogic PET Services of Montreal Company); refer to that product's Product Monograph for a summary of clinical trial data for the CRP[9].

DETAILED PHARMACOLOGY

The hydroxyl group of the second carbon of glucose can be substituted by a group such as hydrogen or fluorine without seriously compromising the kinetic and biochemical ability of the molecule to be actively transported through the cell membrane and to act as a substrate for the hexokinase enzyme. The 2-deoxy analogues of glucose are transported into the cell and metabolized quantitatively exactly like D-glucose up the point in the glycolytic pathway where its anomalous structure prevents the final conversion of the 2-deoxyglucose-6-phosphate by phosphohexoseixomeriase[10].

In mice, ^{18}F-FDG distributes uniformly to the kidneys, heart, brain, lungs and liver initially and clears rapidly from all tissue except the heart where it remains constant for at least 2 hours and, to a lesser extent, in the brain where it decreases slowly from 1 to 2 hours[11,12]. The rapid clearance of ^{18}F-FDG from the liver, lungs and kidneys, and its retention by the heart and brain is a result of metabolic trapping within these organs and is reflective of glucose utilization. Urinary excretion of intact 18F-FDG was 15-25% of injected dose at 90 minutes.

In mice, ^{18}F-FDG accumulates in organs and fluids as parent FDG (or FDG-6-phosphate) and FD-Mannose (or FD-Mannose-6-phosphate) and is excreted in the urine in both forms[13].

In rats, the percentages of ^{18}F-FDG and ^{18}F-FDG-6-phosphate 45 minutes after injection were 68 and 33%, respectively in the liver; and 70 and 27%, respectively, in the kidney[14].

In mice bearing C3H mammary carcinoma the predominant metabolite observed in the tumour at 180 minutes was 18F-FDG-6-phosphate, with measurable quantities of other phosphorylated species[15].

TOXICOLOGY

'Cold' 2-deoxy-2-fluoro-D-glucose had an LD50 of 600 mg/kg in both mice and rats when given by intraperitoneal injection in 5 or 6 consecutive daily doses[16].

Toxicity studies in mice given three doses of 14.3 mg/kg of FDG did not reveal any immediate or long-term effects as determined by routine observations, changes in body weight, and gross and histopathology of the internal organs. Toxicity studies in dogs injected with three doses of 0.72 mg/kg of FDG did not show any immediate or long-term effects. No significant abnormalities were detected in blood, urine, or CSF analyses and no significant gross or microscopic abnormalities were detected in the heart, brain, spleen, liver, kidneys, lungs, ovaries, or intestines[17].

No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether ^{18}F-FDG affects fertility in males or females.

As with other radiopharmaceuticals that distribute intracellularly, there may be increased risk of chromosome damage from Auger electrons if nuclear uptake occurs.

REFERENCES

1) International Commission on Radiological Protection. Pregnancy and Medical Radiation. ICRP Publication 84. Annals of the ICRP 2000; 30(1):1
2) Pattern of uptake and excretion of (18)F-FDG in the lactating breast; Hicks RJ, Binns D, Stabin MG. J Nucl Med. 2001 Aug;42(8):1238-42.
3) a) Silberstein EB. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Edward B. Silberstein and Janet Ryan Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1998 Dec; 39(12): 2190-2
b) Pharmacopeia Committee of the SNM: ***Adverse Reactions Table.***
http://interactive.snm.org/index.cfm?PageID=1446
c) Positron-Emitting Radiopharmaceuticals: How Safe Are They?; Edward B. Silberstein; Cancer Biotherapy & Radiopharmacy Volume 16, Number 1, 2001, p.13.
d) Dr. E.B. Silberstein, 1997:
http://www.fda.gov/ohrms/dockets/dockets/98d0266/c000003c.pdf
4) MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG; Hays MT, Watson EE, Thomas SR, Stabin M.. J Nucl Med 2002; 43:210-4
5). Proposed Addendum to Previously Published Fetal Dose Estimate Tables for 18F-FDG. Stabin MG. J Nucl Med 2004; 45:634–635
6) A mathematical model for the distribution of fluorodeoxyglucose in humans. Hays MT, Segall GM. .J Nucl Med. 1999 Aug; 40(8):1358-66.
7) The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. J Nucl Med. 1982 Jul; 23(7):613-7
8) Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. J Nucl Med. 1991 Apr;32(4):699-706.
9) ^{18}F-Fluorodeoxyglucose [^{18}F-FDG], Canadian Product Monograph, Date of Authorization: November 26, 2008. (Manufacturer; PharmaLogic P.E.T. Services of Montreal Company).
10) Positron-emission tomography with [18F]fluorodeoxyglucose: Part I. Biochemical uptake mechanism and its implication for clinical studies. Pauwels EKJ, Sturm EJC, Bombardieri E, Cleton FJ, Stokkel MPM. J Cancer Res Clin Oncol 2000; 126:549-59.
11) Metabolic trapping as a principle of radiopharmaceuticals design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. Gallagher BM, Fowler JS, et al. J Nucl Med 1978; 19:1154-61.
12) Radiopharmaceuticals XXVII. 18F-labelled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: Tissue distribution and imaging studies in animals. Gallagher BM, Ansari A, Atkins H, et al., J Nucl Med 1977; 18:990-6.
13) Metabolic pathway of 2-deoxy-2-fluoro-D-glucose studied by F-19 NMR. Kanazawa Y, Momozono Y, Ishikawa M, et al. Life Sciences 1986; 39:737-42

14) Metabolism of 2-[18F]fluoro-2-deoxyglucose in tumor-bearing rats: Chromatographic and enzymatic studies. Suolinna E-M, Haaparanta M, Paul R, et al. Nucl Med Biol 1986; 13:577-81.
15) Metabolic fate of 18F-FDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma. Kaarstad K, Bender D, Bentzen L, et al. J Nucl Med 2002; 43:940-7.
16) Some in vivo and in vitro antitumor effects of the deoxyfluoro-D-glucopyranoses. Bessell EM, Courtney VD, Foster AB, et al. Eur J Cancer 1973; 9:463-70.
17) The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. Circ Res. 1979 Jan;44(1):127-37.

PART III: CONSUMER INFORMATION

<AtlantiScan>
(**^{18}**F-Fluorodeoxyglucose, ^{18}F-FDG)

This leaflet is part III of a three-part "Product Monograph" published when AtlantiScan was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about AtlantiScan. Contact your doctor or pharmacist if you have any questions about the drug**.**

Serious Warnings and Precautions

AtlantiScan should be used only by those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.

AtlantiScan should not be administered to pregnant women unless it is considered that the benefits to be gained outweigh the potential hazards to the foetus.

Breastfeeding should be discontinued, and close contact between mother and infant avoided, for a period of 12 hours following an AtlantiScan scan.

ABOUT THIS MEDICATION

What the medication is used for:
AtlantiScan or ^{18}F-FDG, is used to study how different tissues in your body are using blood sugar (glucose). The approved use is to study abnormalities found in the lung by other tests (e.g., chest x-ray).

What it does:
AtlantiScan behaves just like blood sugar (glucose) but because it has a radioactive atom, its behaviour can be followed with a special camera (PET).

When it should not be used:
AtlantiScan should not be used in patients allergic to ^{18}F-FDG.

What the medicinal ingredient is:
^{18}F-Fluorodeoxyglucose (^{18}F-FDG)

What the important nonmedicinal ingredients are:
There are no important non-medicinal ingredients.

WARNINGS AND PRECAUTIONS

BEFORE you receive AtlantiScan talk to your doctor or pharmacist if you think you might be pregnant or if you are diabetic.

^{18}F-FDG is not present in dangerous amounts in breast milk but high radioactivity is present in the breast tissue.

Breastfeeding should be discontinued, and close contact between mother and infant avoided, for a period of 12 hours following an ^{18}F-FDG PET scan.

To help eliminate AtlantiScan quickly after the procedure, you should drink a large glass of water and urinate frequently after you receive the injection. Males should use a toilet rather than a urinal. Toilets should be flushed several times. Hands should be thoroughly washed. If blood, urine or feces soil clothing, the clothing should be washed separately from other clothing.

INTERACTIONS WITH THIS MEDICATION

Drug-drug interactions with AtlantiScan have not been evaluated.

PROPER USE OF THIS MEDICATION

This product will be administered under the supervision of a health professional that is experienced in the use of radiopharmaceuticals.

Diabetic patients should ensure that their blood sugar levels are stable the day preceding and the day of the PET scan with ^{18}F-FDG product.

You may be asked to eat nothing and drink only water for four hours before your scheduled PET scan with ^{18}F-FDG product.

To decrease the radiation exposure to your bladder, you should drink plenty of water and urinate as often as possible when the PET scan is finished.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

AtlantiScan is called a 'tracer' meaning that it is given in very small doses and has no activity of its own. Other than possible adverse reactions related to receiving an injection, adverse reactions have not been reported for AtlantiScan.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by:
toll-free telephone: 866-234-2345
toll-free fax 866-678-6789
By email: cadrmp@hc-sc.gc.ca
By regular mail:
National AR Centre
Marketed Health Products Safety and Effectiveness
Information Division
Marketed Health Products Directorate
Tunney's Pasture, AL 0701C
Ottawa ON K1A 0K9

NOTE: Before contacting Health Canada, you should contact your physician or pharmacist.

MORE INFORMATION

This document plus the full product monograph prepared for health professionals can be found at:

or by contacting the sponsor,
Nova Scotia Health Authority, at: 1-902-473-1795
This leaflet was prepared by Nova Scotia Health Authority,
Last revised: April 30. 2015.